Research Output

Antiviral therapeutic approaches for human rhinovirus infections

  Human rhinoviruses (RV) are the primary etiological agent of the common cold. This infection can be mild and self-limiting in immunocompetent hosts, but can be associated with bronchiolitis in infants, pneumonia in the immunosuppressed, and exacerbations of pre-existing pulmonary conditions such as asthma or chronic obstructive pulmonary disease. Many of these conditions can place significant economic costs upon healthcare infrastructure. There is currently no licenced vaccine for rhinovirus, as the large variety of RV serotypes has posed significant challenges for research. In this review we discuss current knowledge around antiviral drugs and small molecule inhibitors of rhinovirus infection, as well as antiviral host defence peptides as exciting prospects to approach the development of novel therapeutics which target human rhinovirus.

  • Type:

    Review

  • Date:

    12 June 2018

  • Publication Status:

    Published

  • DOI:

    10.2217/fvl-2018-0016

  • Cross Ref:

    10.2217/fvl-2018-0016

  • ISSN:

    1746-0794

  • Library of Congress:

    QR180 Immunology

  • Dewey Decimal Classification:

    616 Diseases

  • Funders:

    Chief Scientists Office

Citation

Casanova, V., Sousa, F. H., Stevens, C., & Barlow, P. G. (2018). Antiviral therapeutic approaches for human rhinovirus infections. Future Virology, doi:10.2217/fvl-2018-0016. ISSN 1746-0794

Authors

Keywords

rhinovirus, peptide, antiviral drugs, cathelicidin, interferon, vitamin D

Monthly Views:

Available Documents